The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Patient risk stratification in CLL and selection of treatment approaches
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, discusses patient risk stratification in chronic lymphocytic leukemia (CLL), drawing focus on the role of TP53 mutation, del(17p), and IgHV mutational status, and how these prognostic factors influence treatment approaches. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
